Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center

BACKGROUND: Eribulin improves survival in pre-treated HER2-negative advanced breast cancer (ABC). However, limited data exist on co-morbidities and central nervous system (CNS) efficacy. The purpose of this study was to review eribulin’s efficacy and safety in everyday clinical practice with special...

Descripción completa

Detalles Bibliográficos
Autores principales: Sirvén, Milana Bergamino, Fernández-Ortega, Adela, Stradella, Agostina, Morilla, Idoia, Falo, Catalina, Vázquez, Silvia, Castany, Roser, Villanueva, Rafael, Recalde, Sabela, Pérez, Valentí Navarro, Gil-Gil, Miguel, Pernas, Sonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868802/
https://www.ncbi.nlm.nih.gov/pubmed/31753013
http://dx.doi.org/10.1186/s40360-019-0367-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868802/
https://www.ncbi.nlm.nih.gov/pubmed/31753013
http://dx.doi.org/10.1186/s40360-019-0367-x

Ejemplares similares